Compare WAL & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAL | SYRE |
|---|---|---|
| Founded | 1994 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 8.5B |
| IPO Year | 2005 | 2015 |
| Metric | WAL | SYRE |
|---|---|---|
| Price | $77.56 | $87.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 12 |
| Target Price | ★ $91.69 | $85.08 |
| AVG Volume (30 Days) | 810.7K | ★ 945.1K |
| Earning Date | 04-21-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.11% | N/A |
| EPS Growth | ★ 23.13 | N/A |
| EPS | ★ 3.99 | N/A |
| Revenue | ★ $135,800,000.00 | N/A |
| Revenue This Year | $20.49 | N/A |
| Revenue Next Year | $8.08 | N/A |
| P/E Ratio | $19.58 | ★ N/A |
| Revenue Growth | ★ 99.71 | N/A |
| 52 Week Low | $65.82 | $14.51 |
| 52 Week High | $97.23 | $110.18 |
| Indicator | WAL | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 37.10 | 32.38 |
| Support Level | $73.93 | $81.65 |
| Resistance Level | $84.75 | $106.10 |
| Average True Range (ATR) | 1.61 | 4.60 |
| MACD | -0.33 | -2.56 |
| Stochastic Oscillator | 3.94 | 9.59 |
Western Alliance Bancorp provides a full spectrum of customized loan, deposit, and treasury management capabilities, including funds transfer and other digital payment offerings. The company's reportable segments are Commercial segment includes provides commercial banking and treasury management products and services to small and middle-market businesses, specialized banking services to sophisticated commercial institutions and investors within niche industries, as well as financial services to the real estate industry. Consumer Related segment offers both commercial banking services to enterprises in consumer-related sectors and consumer banking services, such as residential mortgage banking and Corporate & Other.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.